Engineered materials: which startup is ahead?
In our synthetic biology market deck, you will find everything you need to understand the market
SUMMARY
CuspAI is ahead in engineered materials today, with Lila Sciences the only startup close enough to take the lead quickly.
The lead does not come from one model or funding round. CuspAI combines industrial access, category breadth, rapid expansion and the strongest externally confirmed discovery programme in the group.
No startup controls the full materials-development loop yet. Citrine is strongest in enterprise software, Chemify in programmable synthesis, Lila in autonomous experimentation and Orbital in open technical models tied to industrial hardware.
Citrine’s fourth-place ranking hides an important fact: it has the best proof of repeated commercial use. Its long deployments with materials and chemical companies make it the safest business here, even if it is not the fastest-growing one.
Chemify has gone furthest in turning digital designs into routine physical work. Its Glasgow Chemifarm already links route planning, robotic synthesis, testing and analysis inside one operating system.
Lila may be building the deepest long-term moat because every experiment can create private data for the next one. The catch is that its strongest discoveries still lack the outside detail needed to compare them properly.
Orbital has the clearest reproducible technical evidence and a focused route into data-centre hardware. Its models are unusually open, but large repeat product orders remain unproven.
Capital efficiency changes the ranking. Citrine, Chemify and MatNex have produced substantial visible output with far less funding, while Periodic Labs has raised $300 million without showing enough public operating evidence.
The whole field still lacks the decisive proof: several AI-designed materials reaching dependable industrial volumes and generating large repeat orders. Until that happens, the leaders are discovery platforms rather than proven materials manufacturers.
CuspAI therefore leads, but the position is catchable. Named repeat customers, independently tested materials and reliable production economics would matter more now than another large financing round.
This market map, featured in our synthetic biology market deck, highlights top companies and startups in the synthetic biology market
Which engineered-materials startups are we really comparing?
The useful comparison today is between AI-native startups that can repeatedly design and validate new materials, rather than every company selling one better battery, coating, composite or chemical.
We include CuspAI, Lila Sciences, Periodic Labs, Chemify, Citrine Informatics, Orbital Industries and MatNex. Each company is building a platform that can tackle several materials or chemistry problems, rather than betting the whole business on one finished material.
Their approaches still differ widely. CuspAI and Citrine work closely with industrial R&D teams. Lila and Periodic are building autonomous laboratories. Chemify connects digital designs to robotic chemical synthesis. Orbital uses its models to develop its own industrial hardware. MatNex turns industrial specifications into protectable material designs.
We exclude Sila, Lyten, Boston Materials, 6K and similar startups because they mainly compete within one product market. We also exclude Google DeepMind, Meta, Microsoft and government laboratories because they are not startups. XtalPi is now publicly listed, while younger companies such as Entalpic and Kebotix still disclose too little comparable commercial evidence.
Funding figures for private companies are rarely perfect. We use completed and publicly announced rounds wherever possible, with cautious wording when company filings and databases disagree.
| Startup | What it does | Publicly traceable funding | Why it belongs |
|---|---|---|---|
| CuspAI | Designs materials with generative AI, simulations and industrial laboratory partners | At least $580 million in announced rounds | Broadest industrial AI materials platform in the group |
| Lila Sciences | Runs AI Science Factories that design, conduct and learn from experiments | $550 million | Best-funded autonomous-science challenger |
| Periodic Labs | Builds AI scientists and laboratories for physical-science experiments | $300 million | Major new autonomous-lab entrant |
| Chemify | Converts molecular designs into chemical code executed by robotic systems | At least $93 million | Clearest link between software and automated synthesis |
| Citrine Informatics | Provides AI software for materials and chemical product development | About $80 million | Longest commercial history in materials informatics |
| Orbital Industries | Uses AI-designed materials in cooling and data-centre infrastructure | At least $66 million | Strongest direct path from AI models to industrial hardware |
| MatNex | Designs critical materials to specification using AI and physics models | Around $16 million according to recent company evidence | Small but unusually productive focused challenger |
Is one engineered-materials startup clearly ahead today?
CuspAI is currently ahead overall, although Lila Sciences remains close enough to make this a real contest.
CuspAI combines more capital, a broader industrial network and stronger external project validation than any direct rival. Its AI Materials Foundry has brought together more than 45 organisations across computing, chemicals, semiconductor equipment, manufacturing, scientific data and laboratory testing.
The names carry unusual weight. NVIDIA and Meta provide AI infrastructure and models. Applied Materials, Lam Research and Tokyo Electron understand semiconductor manufacturing. Hyundai, 3M, Merck, Mitsui Chemicals, Fujifilm and Oxford PV bring real materials problems and possible routes to market.
CuspAI has also completed a six-month discovery project with Kemira. Kemira confirmed that the system screened a vast materials space and produced a small group of candidates for removing PFAS from water.
Lila has a different advantage. Its AI Science Factories bring models and experiments under one roof, allowing each laboratory result to improve the next decision. That closed loop could eventually become more powerful than CuspAI’s distributed partner model.
The financial gap barely separates them. CuspAI has announced at least $580 million across its major rounds, while Lila has raised $550 million.
CuspAI leads because it has more named industrial relationships and one externally confirmed programme with detailed outputs. Lila has announced impressive internal discoveries, but less public evidence from paying materials customers.
If you want more recent data on this point, please see our latest synthetic biology market report.
As this chart shows, and as featured in our synthetic biology market deck, search interest in gene editing has grown significantly
Which engineered-materials startup has the strongest commercial traction and customers?
Citrine currently has the strongest proof of repeated industrial use, while CuspAI has assembled the most valuable new customer pipeline.
Citrine has spent years working inside materials and chemical companies such as Panasonic, LyondellBasell, Eastman, LANXESS, Stepan and Electroninks. Its projects cover semiconductors, formulations, coatings, polymers and specialty chemicals.
The Panasonic case remains one of the clearest examples. Citrine helped create four patent-pending organic semiconductor candidates, including one with 25% higher hole mobility than Panasonic had previously achieved.
Stepan has described using Citrine models to answer formulation requests more quickly. Electroninks worked with the platform to improve silver inks. These cases show that Citrine can fit into ordinary industrial R&D rather than remaining an experimental tool.
CuspAI’s customer and partner roster is more strategically powerful. Applied Materials, Lam Research, Tokyo Electron, Kioxia and imec bring semiconductor expertise. Hyundai and Goodyear bring automotive problems. Merck, Mitsui Chemicals, Resonac, Umicore and Johnson Matthey bring chemistry and manufacturing knowledge.
The variety is valuable because materials development requires scientific data, computing, laboratory instruments, process engineers and eventual buyers. CuspAI has pulled all of those groups into one ecosystem.
However, membership in the Foundry does not prove that every company is a paying customer. Some organisations may provide data or laboratory access, while others may run joint research or early evaluations.
Chemify’s partnership with Zeon carries more weight than a loose innovation agreement. Zeon invested in Chemify and plans to use its design and synthesis system for advanced materials.
Orbital’s relationships with AWS and NVIDIA fit its focus on AI data centres, but the company has not disclosed meaningful shipment volumes or repeat orders. Lila has started opening its platform to customers, although named materials clients remain scarce.
Citrine wins on proven customer depth. CuspAI wins on the quality and potential value of its industrial network.
Which engineered-materials startup is growing fastest and has the most momentum?
CuspAI is currently expanding faster than any rival across funding, valuation, hiring, partnerships and international reach.
CuspAI started with a $30 million seed round, followed with a Series A of more than $100 million and recently closed a $450 million Series B. The latest round alone was fifteen times the size of the original seed financing.
Its reported valuation moved from approximately $520 million to $2.6 billion in less than a year, a fivefold increase. That growth has been accompanied by operations or hiring across the United States, Singapore, Amsterdam, Berlin and Tokyo.
The company is also adding advisers with experience at Apple, Google, AMD and major industrial groups. It appears to be preparing to run several large programmes at once rather than relying on one flagship project.
Lila grew almost as dramatically when it moved from a $200 million seed round to $550 million in total funding. The company is using that money to add instruments, expand its Science Factories and open the platform to external customers.
Orbital has the strongest momentum among the smaller startups. Its latest $50 million Series B was more than three times larger than its earlier $16 million Series A. It has also announced work with NVIDIA, released OrbMol-v2 and focused its commercial strategy on data-centre cooling and modular infrastructure.
Chemify has had a productive recent period as well. Zeon invested and became a materials partner, the company added more discovery programmes, and its latest financing supports a planned Silicon Valley facility.
Citrine’s launch of Catalyst and Apex shows that the older startup is still shipping meaningful products. Lila has deepened its work with NVIDIA’s scientific-agent infrastructure, while MatNex has published new research on magnetic simulations and superconductor design.
Periodic continues to hire and build, but it has released little evidence of what its laboratories have produced.
CuspAI has the strongest overall momentum. Orbital’s recent moves are narrower but unusually consistent around one commercial market.
If you want more recent data on this point, please see our latest synthetic biology market report.
This chart, featured in our synthetic biology market deck, illustrates yearly VC funding for synthetic biology startups
Which engineered-materials startup has moved furthest into the real world?
Chemify has moved furthest into daily physical operations, while CuspAI has completed the strongest recent industrial discovery programme.
Chemify operates a £12 million, approximately 21,500-square-foot automated chemistry facility in Glasgow. The Chemifarm connects molecular design, route planning, robotic synthesis, testing and analysis inside one operating system.
A partner can ask Chemify for a molecule and receive a physical compound rather than stopping with a digital structure. Chemify says its automated process can shorten the path from an initial idea to synthesis by roughly ten times, although the result depends heavily on the molecule.
CuspAI’s work with Kemira shows another form of maturity. The project began with approximately 300 trillion possible metal-organic framework structures for PFAS removal. CuspAI generated more than 5,000 designs and reduced the search to around 20 priority candidates within six months.
Those candidates still need to be manufactured cheaply, survive repeated use and beat existing filtration materials. Even so, CuspAI has already taken an industrial problem much further than a general AI demonstration.
Lila’s Science Factories appear to offer the strongest autonomous experimentation system. Its models generate hypotheses, choose experiments, operate instruments and learn from the results. Lila now sells access through its Catalyst product and a laboratory-as-a-service model.
MatNex provides a useful smaller-scale example. The company designed and physically produced MagNex, a rare-earth-free permanent magnet, with the University of Sheffield and the Henry Royce Institute. MatNex says the work took about three months after screening more than 100 million possible compositions.
No company has yet shown the whole process repeatedly, from AI design to dependable mass production and large repeat orders. That is still the missing piece.
Which AI materials startup has the best technical evidence?
Orbital Industries currently offers the clearest reproducible model evidence, even though CuspAI and Lila are tackling broader scientific problems.
Orbital open-sourced its original Orb model and published results against recognised materials benchmarks. The company reported simulations three to six times faster than previous universal interatomic potentials and a 31% reduction in error on the Matbench Discovery benchmark.
Orbital has continued releasing new versions. Orb-v3 extended simulations toward larger physical systems, while newer OrbMol models target molecular chemistry. Orbital recently claimed that OrbMol-v2 beat a widely cited chemistry method, although that comparison still comes from the company.
The open releases allow outside researchers to inspect and challenge Orbital’s work, giving its claims more weight than results that remain entirely inside a private laboratory.
Citrine has a stronger application-level result. Panasonic’s four patent-pending candidates and 25% improvement in hole mobility relate directly to a property that could influence semiconductor performance.
Lila reports carbon-capture materials with better capacity, thermal stability and binding speed than leading products. It also says its laboratories found lower-cost catalysts that avoid platinum-group metals. These results could matter more than Orbital’s benchmark lead, but Lila has not released enough experimental detail for a proper comparison.
MatNex has lately published more of its research. Its work on magnetic machine-learning potentials aims to simulate defects, temperature effects and complex spin states at close to quantum-level accuracy but far lower computational cost. Another project used reinforcement learning to explore new superconductor families.
CuspAI has shown that it can search enormous design spaces. The remaining test is whether the resulting materials consistently perform better when made and tested.
If you want more recent data on this point, please see our latest synthetic biology market report.
This chart, featured in our synthetic biology market deck, shows how Twist Bioscience is capturing share in synthetic biology
Which engineered-materials startup has the clearest way to make money at scale?
Citrine has the clearest route to recurring revenue, while CuspAI and Orbital could eventually build larger but less predictable businesses.
Citrine sells enterprise software that becomes part of a company’s materials-development process. Licences, implementation, additional users and expansion into more departments create a familiar recurring model. Software can also reach another customer without building another laboratory.
Citrine recently launched Catalyst and Apex, two tools that turn a product goal into suggested experiments and improve predictive modelling behind the workflow. The products make the platform easier for materials teams to use without becoming machine-learning experts.
CuspAI can probably charge through long-term research programmes, platform access, milestone payments and possibly rights linked to valuable discoveries. A successful semiconductor material or industrial catalyst could support a very large contract. The company has not explained which revenue structure will dominate.
Lila now has a more visible offer. Catalyst gives companies access to its scientific agents, experts and Science Factories. Its laboratory-as-a-service model lets customers buy experimental capacity without constructing their own autonomous facility.
Chemify can earn money from molecular design, synthesis and manufacturing services. Its next challenge is replication. The Glasgow Chemifarm needs to stay busy, and the planned Silicon Valley hub must reproduce the same automated processes reliably.
Orbital sells physical products rather than access to a discovery platform. Cooling fluids, thermal systems and modular infrastructure can produce large order values, especially as AI data centres consume more power. The model also brings factories, inventory, installation, warranties and maintenance.
Citrine has the safest and most scalable business model today. CuspAI has the largest potential contract value, while Orbital has the clearest path to substantial hardware revenue.
Which engineered-materials startup uses its funding most effectively?
Citrine and Chemify currently show the best visible output per dollar, while Periodic has the most to prove.
Funding efficiency remains difficult to measure because these startups do not disclose revenue, cash burn or research spending. We can still compare capital raised with operating facilities, external customers, validated outputs and commercial products.
Citrine has spent roughly a decade building enterprise deployments on about $80 million. Its latest product release shows that the company is still improving the platform rather than relying only on old case studies.
As seen above, Chemify already operates a large automated facility and is preparing a second hub after raising at least $93 million. Its scientific papers, strategic investment from Zeon and new discovery agreements suggest that the infrastructure is being used.
Orbital has raised at least $66 million and produced open models, commercial infrastructure products and strategic work with AWS and NVIDIA. The real test will come from customer shipments.
MatNex has created a physical material and published new technical work with much less capital. Its recent company evidence puts total funding around $16 million, although public investment databases often show lower amounts.
CuspAI has announced at least $580 million. That money has produced a broad industrial platform and a detailed discovery programme, but expectations are now far higher.
Lila has raised $550 million and built working Science Factories. Its scientific claims are ambitious, yet external customer evidence remains limited.
Periodic raised $300 million at launch. The company may be building substantial laboratories behind closed doors, but outsiders currently see almost no customer work, benchmark, material or operating milestone.
| Startup | Approximate funding | Best visible output from that capital | Current judgment |
|---|---|---|---|
| Citrine | About $80 million | Long customer history, patent-generating projects and a mature software platform | Strongest commercial efficiency |
| Chemify | At least $93 million | Operating Chemifarm, external programmes and expansion plans | Strong |
| Orbital | At least $66 million | Open models, hardware products and relevant infrastructure partners | Promising, with sales still unproven |
| MatNex | Around $16 million | A physically produced magnet and recent materials research | High early output for its size |
| CuspAI | At least $580 million | Industrial discovery programme and broad operating ecosystem | Strong progress, very high expectations |
| Lila Sciences | $550 million | Autonomous laboratories and internally validated discoveries | Technically impressive, commercially opaque |
| Periodic Labs | $300 million | Team and autonomous-lab development | Weakest public output relative to funding |
If you want more recent data on this point, please see our latest synthetic biology market report.
This chart, featured in our synthetic biology market deck, illustrates yearly funding for synthetic biology startups
Which engineered-materials startup has the strongest moat?
Lila may be building the deepest long-term moat, while CuspAI currently controls the strongest industrial ecosystem.
A materials model can be copied much faster than years of experimental results. Public databases are also growing rapidly, and large technology companies already release capable materials models.
Lila’s Science Factories can generate private information that cannot be scraped from academic papers. Failed experiments, unusual processing conditions and repeated measurements may teach the system more than a database containing only successful published results.
If Lila runs more useful experiments than its rivals, that private dataset could compound into a major advantage.
CuspAI’s Foundry creates another type of protection. The company has access to industrial problems, specialist laboratories, trusted scientific data, computing infrastructure and potential buyers. A competitor may reproduce parts of the model but still struggle to assemble the same relationships.
Those relationships may not be exclusive. A large chemical or semiconductor company can work with CuspAI while building internal systems or hiring another startup. CuspAI needs to become deeply embedded in customer programmes before the ecosystem becomes difficult to leave.
Chemify’s protection comes from executable chemical recipes, robotic systems, synthesis data and operating knowledge. Citrine benefits from customer integration, since replacing the software becomes disruptive once a company has cleaned its data and changed its R&D workflow.
Orbital has opened much of its model work, so its lasting advantage must come from proprietary formulations, product engineering, manufacturing and deployments. MatNex can protect specific material compositions and industrial applications through patents.
Lila has the strongest potential data moat. CuspAI has the strongest practical position today.
Who leads each part of the engineered-materials startup market?
Engineered materials still has several specialised winners, even with CuspAI ahead overall.
A chemical company asking for a synthesised molecule may prefer Chemify. A manufacturer organising years of internal testing data may get faster value from Citrine. A data-centre operator looking for cooling hardware belongs closer to Orbital.
Lila and Periodic are making a broader bet on autonomous laboratories. CuspAI sits between these models by coordinating external data, laboratories, models and industrial demand.
Each startup therefore controls a different step between defining the problem, designing a candidate, running an experiment and manufacturing a product.
| Part of the market | Current leader | Why it leads | Closest challenger |
|---|---|---|---|
| Industrial materials discovery | CuspAI | Broadest access to large industrial problems and specialised partners | Citrine |
| Autonomous experimentation | Lila Sciences | Most developed commercial vision for AI-run Science Factories | Chemify |
| Programmable chemical synthesis | Chemify | Operating robotic system that turns chemical code into compounds | Lila Sciences |
| Enterprise materials software | Citrine Informatics | Longest commercial deployment history | CuspAI |
| Transparent materials models | Orbital Industries | Open releases and published benchmark comparisons | MatNex |
| AI-designed industrial hardware | Orbital Industries | Cooling and data-centre products already offered to partners | MatNex |
| Focused critical-material design | MatNex | Clear ability to design physical materials against industrial requirements | CuspAI |
| Funding and overall expansion | CuspAI | Fastest combination of capital growth, hiring and geographic expansion | Lila Sciences |
This chart, featured in our synthetic biology market deck, compares the main business model options for synthetic biology platforms
How much can we trust the engineered-materials startup evidence?
The engineered-materials ranking is reliable at the top, but the exact gaps remain uncertain because almost every startup hides its most useful business numbers.
None of the seven companies regularly discloses revenue, customer retention, gross margins, laboratory utilisation or repeat order values. We therefore cannot calculate a credible market share or compare revenue growth.
The strongest evidence comes from completed financing rounds, operating facilities, named customer projects, public technical papers, open models and results confirmed by an industrial partner.
Citrine’s Panasonic work fits that standard because the customer, performance improvement and patent outcome are known. Orbital’s open models can be tested by outside researchers. Kemira’s public description of its CuspAI project gives the discovery programme more credibility than a normal startup case study.
Company-reported science requires more caution. Lila’s carbon-capture and catalyst results sound important, but outsiders cannot yet inspect the full datasets. MatNex’s development-time, cost and carbon comparisons for its magnet also come mainly from the company and its partners.
Partnership language creates another problem. Companies use the same word for a paid project, joint research, investment, data sharing or early evaluation. We therefore give more weight to projects with named outputs than to the number of logos on a website.
Funding totals are also uneven. Directly announced CuspAI rounds add up to at least $580 million, while some reports place the total above $650 million. MatNex has described raising around $16 million, although several databases still record only its smaller public equity rounds.
The biggest missing proof is mass production. No startup here has publicly shown several AI-designed materials reaching dependable industrial volumes and generating large repeat orders.
Which engineered-materials startups are actually ahead?
CuspAI is ahead overall today, with Lila Sciences as the only challenger close enough to change the answer quickly.
CuspAI has the best combined evidence across industrial demand, category coverage, growth, customer quality and externally confirmed discovery work. The company has moved beyond a promising materials model, although it still has to prove that its candidates work reliably in factories and customer products.
Lila ranks second because its autonomous laboratories could create a more powerful learning system. Several independently verified materials and named repeat customers would put Lila level with CuspAI or ahead of it.
Chemify deserves third place. It has already connected software, robotics and physical chemistry inside an operating facility. Its next step is showing that the model works across several busy sites and produces reliable commercial revenue.
Citrine ranks fourth because it remains the safest commercial business in the group. Its customers already use the platform inside real R&D work. Its slower growth and lighter control over physical experiments keep it below Chemify.
Orbital sits just behind Citrine. Its models are unusually open, and its data-centre products give the company a direct commercial target. Large hardware deployments would move Orbital into the top three.
MatNex ranks sixth. It has achieved a lot with comparatively little money, but one notable material does not yet establish a broad discovery platform.
Periodic ranks last for now. Its team and capital make it a serious future contender, yet the current ranking has to reward completed work rather than expected breakthroughs.
For now, CuspAI is the most convincing engineered-materials leader. The gap over Lila is meaningful, while the distance to the remaining startups is already much larger.
| Rank | Startup | Current position | Why it ranks here |
|---|---|---|---|
| 1 | CuspAI | Clear but catchable leader | Strongest overall mix of industrial validation, customer access, growth and category breadth |
| 2 | Lila Sciences | Close challenger | Best autonomous-lab strategy and strongest potential proprietary-data advantage |
| 3 | Chemify | Leader in physical chemistry automation | Operating connection between AI design, robotic synthesis and real compounds |
| 4 | Citrine Informatics | Commercial software leader | Longest enterprise history and clearest recurring business model |
| 5 | Orbital Industries | Fast-rising product challenger | Transparent models and a focused route into data-centre hardware |
| 6 | MatNex | Productive specialist | Strong technical output for its size, but limited commercial and manufacturing evidence |
| 7 | Periodic Labs | High-potential early entrant | Exceptional capital and talent, with too little public operating evidence so far |
If you want more recent data on this point, please see our latest synthetic biology market report.
This chart, featured in our synthetic biology market deck, illustrates the share of revenue generated by each customer segment in the synthetic biology market
OUR METHODOLOGY
This analysis asks which engineered-materials startup is ahead based on evidence that shows real progress from computational design toward experimentation, industrial adoption and repeatable economic value.
We compared commercial traction, industrial validation, technical evidence, physical execution, growth, business-model scalability, capital efficiency and long-term defensibility. The final ranking aggregates those conclusions rather than allowing one funding round, partnership, benchmark or product announcement to decide the result.
We prioritised completed financing, named industrial programmes, measurable project results, operating facilities, released models, physical materials, commercial products and evidence confirmed by customers or research partners. Broad partnership language, undisclosed internal results and claims that outsiders cannot examine received less weight.
The companies follow different models, so we did not force them into one operating template. Enterprise software, autonomous laboratories, programmable synthesis and vertically integrated hardware can all lead, but each company must show progress appropriate to the part of the discovery and production process it wants to control.
Recent demonstrated progress carries more weight than theoretical potential. Longer-term advantages, such as proprietary experimental data or industrial ecosystem access, count when there is credible evidence that those advantages are already beginning to form.
Key sources include CuspAI’s company and AI Materials Foundry materials, Kemira’s confirmation of the PFAS discovery programme, Lila Sciences’ Series A announcement, Lila Catalyst, Lila’s Science Factory technology overview, Chemify’s company and Chemifarm overview, Chemify’s financing and partnership announcements, Orbital Industries’ Series B announcement, Orb’s technical introduction and benchmark results, the Orb-v3 release, Orbital’s AWS partnership, and the NVentures investment announcement.
Funding totals are treated as approximate when public announcements, company evidence and private-market databases disagree. We use the most directly traceable completed rounds available and avoid turning small differences in cumulative funding into false precision.
This chart, featured in our synthetic biology market deck, shows how gene therapy technology has evolved over time
Related blog posts
